Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients.
Read moreLaminar Pharma opens a new financing round of up to seven million euros. The objective is to finish financing the development of its drug LAM561 against the most aggressive and common brain cancer, gl...
Read moreEl Instituto de Investigación Sanitaria INCLIVA, del Hospital Clínico Universitario de València, ha impulsado un ensayo clínico para evaluar la seguridad y la tolerabilidad del anticuerpo blinatum...
Read moreTheriva™ Biologics has announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate...
Read moreInvestigadores del Cima Universidad de Navarra constatan que la combinación de dos fármacos, ya conocidos, abre el camino a posibles ensayos clínicos para combatir los gliomas difusos de línea med...
Read moreThis article explores the current state of pharmaceutical innovation, predicts future trends, and discusses the role of artificial intelligence in shaping the industry. Furthermore, it highlights the ...
Read moreA clinical trial of CAR-T therapies has brought the word curable almost within touching distance for multiple myeloma, the second most common blood cancer in the world, thus increasing hope and qualit...
Read more